Although clinical trials are yet to be conducted regarding the effectiveness of high-dose toremifene therapy against recurrent breast cancer or postmenopausal hormone-sensitive progressive breast cancer, Fushima et al. show promising research in their study of high dose-toremifene for hormone receptor-positive metastatic breast carcinoma with secondary resistance to aromatase inhibitors (112). The gene discussed is CYP19A1; the disease is breast carcinoma.